Moclobemide is a monoamine oxidase inhibitor used in the treatment of major depressive disorder and bipolar disorder. Most meta-analyses and most studies indicate that in the acute management of depression, moclobemide is more efficacious than placebo medication and similarly efficacious as tricyclic antidepressants (TCA) or selective serotonin reuptake inhibitors (SSRIs).
- Mechanism
- Curator reviewed · 2 references
The mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms.
- Primary indication
- For the treatment of major depressive disorder and bipolar disorder.Curator reviewed · 1 structured indication
- Formula / weight
- C13H17ClN2O2 · 268.739 g/mol (avg)
- First approval
- Canada, 1998
- Also known as
- Moclobemid
- Code names
- GNF-PF-695 · RO 11-1163/000
- Brand names
Resolves to
YHXISWVBGDMDLQ-UHFFFAOYSA-NSMILESClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1What you can answer from here — as of September 23, 2026
Which drugs share a target with Moclobemide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account